™E Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders By Investing.com

BERLIN–(BUSINESS WIRE)–Regulatory News:

™E Pharma N.V. (Euronext Growth Paris: AL™E) (Paris:AL™E), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (™E), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 01.30 p.m. CEST on June 27, 2024, at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.

The annual accounts for the year ending December 31, 2023, and the report of the board of directors for 2023, the convocation to the AGM, the agenda and the explanatory notes to the agenda, the instructions and documents for participation and voting in person or by proxy at the upcoming AGM are available on the company’s website, in a dedicated section of the Corporate Governance page. These documents are also available at the company’s offices at Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany, for shareholders and persons entitled to attend the meeting who, upon request, will receive a copy free of charge.

One item on the agenda at the AGM will be voting on the new supervisory board member nomination. Considering the current development, performance and strategy of the company, the supervisory board has made the binding nomination of Dr. Lee Schalop as the fourth member of the supervisory board.

Dr. Lee Schalop (New York, USA; 60) has a unique combination of biotech development expertise specific to brain cancer and deep financial industry knowledge. He was co-founder of Oncoceutics, a clinical-stage drug discovery and development company with a novel brain cancer drug, and as Chief Executive Officer led a transformative acquisition of the company by Chimerix (NASDAQ:) in January 2021 for $78 million plus up to $360 million in contingent milestone payments and royalties of 15-20% on sales. In addition, Dr. Schalop served as Oncoceutics’ Chief Operating Officer from 2016 to 2020 and as the Chief Business Officer from Oncoceutics’ founding in 2009 until 2016. Prior to co-founding Oncoceutics, Dr. Schalop attended the Albert Einstein College of Medicine, graduating with a doctor of medicine degree in 2008. Before attending medical school, Dr. Schalop spent more than 19 years in the financial industry at a number of major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of America Securities. From 1985 to 1993, he was an investment banker, and his fund-raising activities included more than 10 initial public offerings, the largest of which raised over $700 million. From 1993 to 2004, he served as a research analyst and authored more than 1,000 reports covering more than 50 different publicly traded companies, earning a reputation for groundbreaking research. Dr. Schalop serves as a Board Observer at Chimerix Inc . and sits on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania. He is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University’s Wharton School and College of Arts and Sciences.

Under Dutch law and the company’s Articles of Association, persons entitled to attend and to vote at the AGM are shareholders of the company (which for the purposes of this notice includes holders of a Dutch law right of usufruct) who (i) were registered as a shareholder in one of the administration records of the intermediaries that are (indirectly) participants in Euroclear France on May 30, 2024 (the Registration Date) after all debit and credit entries have been handled as per the Registration Date and (ii) have notified the company by 05.00 p.m. CEST on June 20, 2024, of their attendance in writing or electronically (contact details are available on the company’s website).

About ™E Pharma

™E Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor microenvironment (™E) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the ™E, ™E Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, ™E Pharma is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. ™E Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. US FDA has approved the design of a randomized Phase 2 trial in glioblastoma and ™E Pharma was awarded fast track designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. ™E Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda ® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda ® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in France, Spain and the United States. The company’s second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. ™E Pharma is considering several solid tumors for further clinical development. Further information can be found at: www.tmepharma.com.

™E Pharma ® and the ™E Pharma logo are registered trademarks.

Keytruda ® is a registered trademark of Merck Sharp (OTC:) & Dohme Corp.

Visit ™E Pharma on LinkedIn and Twitter.

About the GLORIA Study

GLORIA (NCT04121455) is ™E Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is ™E Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain “forward-looking statements. Forward-looking statements are based on ™E Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and ™E Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and ™E Pharma undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240526935010/en/

For more information, please contact:
™E Pharma N.V.
Aram Mangasarian, Ph.D., CEO
Tel. +49 (0) 30 16637082 0
investors@tmepharma.com

Investor and Media Relations:
LifeSci Advisors
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com

NewCap
Arthur Rouillé
Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr

Source: ™E Pharma N.V.